The diagnostic significance of hyperfibrinogenemia and thrombocytosis in patients with ovarian tumors/adnexal masses

Bhavana Sontakke; Ruchi Arora; Shilpa M. Patel; Chetana Parekh

doi:10.18203/2320-1770.ijrcog20233290

Authors

Bhavana Sontakke Department of Gynaecological Oncology, Gujarat Cancer Research Institute, Ahmedabad, Gujarat, India
Ruchi Arora Department of Gynaecological Oncology, Gujarat Cancer Research Institute, Ahmedabad, Gujarat, India
Shilpa M. Patel Department of Gynaecological Oncology, Gujarat Cancer Research Institute, Ahmedabad, Gujarat, India
Chetana Parekh Department of Gynaecological Oncology, Gujarat Cancer Research Institute, Ahmedabad, Gujarat, India

DOI:

https://doi.org/10.18203/2320-1770.ijrcog20233290

Keywords:

Adnexal masses, Hyperfibrinogenemia, Ovarian malignancy, Ovarian tumors, Thrombocytosis

Abstract

Background: We aim to study the correlation of thrombocytosis and hyperfibrinogenemia with ovarian tumors and its role in the diagnosis of ovarian malignancy. And to evaluate the platelet and fibrinogen levels in early and advanced stage ovarian disease.

Methods: This is a single centre prospective study. We evaluated plasma fibrinogen levels and plasma platelet levels in 250 patients in women presenting in our OPD with adnexal masses/ovarian tumors. Thrombocytosis was defined as a platelet count greater than >410,000/uL. Hyperfibrinogenemia was defined as a fibrinogen level higher than 360 mg/dL. The association between plasma fibrinogen, platelet levels and clinico-pathological, histopathological parameters were investigated in regards to: 1. Malignant or benign ovarian tumor. 2. Early or advanced disease in malignant ovarian tumors. A multivariate logistic regression model was performed to identify an independent association.

Results: Thrombocytosis and hyperfibrinogenemia are seen to be associated with malignant ovarian tumors. In a multivariate model, plasma fibrinogen and plasma platelet levels were identified to be independently associated with the malignant ovarian tumours. Within the EOC cohort, patients with advanced stage disease had higher plasma fibrinogen levels than patients with early stage.

Conclusions: In this study, we demonstrated that both thrombocytosis and hyperfibrinogenemia were positively associated with malignant ovarian tumors. They were also associated with advanced disease stage, elevated CA125 level and other markers. These finding are in accordance with the previous published data from patients with ovarian cancer, indicating that the platelet and fibrinogen levels increase in parallel with tumor progression and metastasis. Thus confirming the role of elevated platelet and fibrinogen levels in diagnosis and prognosis of ovarian Malignancy.

Metrics

Metrics Loading ...

References

Siegel R. Naishadham D, Jemal A. Cancer statistics 2013. CA Cancer J Clin 2013;63(1):11-30.

Engelen MJ, Kos HE, Willemse PHB, Aalders JG, de Vries EG, Schaapveld M, et al. Surgery by consultant gynecologic oncologists improves survival in patients with ovarian carcinoma. Cancer. 2006;106(3):589-98.

Woo YL, Kyrgiou M, Bryant A, Everett T, Dickinson H. Centralization of services for gynecological cancer–a Chochrane systematic review. Gynecol Oncol. 2012;126(2):286-90.

Alca´zar JL, Castillo G, Jurado M, Garcı´a GL. Is expectant management of sonographically benign adnexal cysts an option in selected asymptomatic premenopausal women. Hum Reprod 2005;20(11):3231-4.

Bristow RE, Smith A, Zhang Z, Chang DW, Crutcher G, Fung ET, et al. Ovarian malignancy risk stratification of the adnexal mass using a multivariate index assay. Gynecol Oncol. 2013;128(2):252-9.

Dearking A, Aletti G, McGree M, Weaver AL, Sommerfield MK, Cliby WA. How relevant are ACOG and SGO guidelines for referral of adnexal mass? Obstet Gynecol. 2007;110(4):841-8.

Dodge JE, Covens AL, Lacchetti C, Elit LM, Le T, Devries-Aboud M, et al. Gynecologic Cancer Disease Site Group. Preoperative identification of a suspicious adnexal mass: a systematic review and meta-analysis. Gynecol Oncol. 2012;126(1):157-66.

Timmerman D, Testa AC, Bourne T, Ferrazzi E, Ameye L, Konstantinovic ML, et al. Logistic regression model to distinguish between the benign and malignant adnexal mass before surgery: a multicentre study by the International Ovarian Tumor Analysis Group. J Clin Oncol. 2005;23(34):8794-801.

Timmerman D, Testa AC, Bourne T, Ameye L, Jurkovic D, Van Holsbeke C, et al. Simple ultrasound based rules for the diagnosis of ovarian cancer. Ultrasound Obstet Gynecol. 2008;31(6):681-90.

Timmerman D, Ameye L, Fischerova D, Epstein E, Melis GB, Guerriero S, et al. Simple ultrasound rules to distinguish between benign and malignant adnexal masses before surgery: prospective validation by IOTA group. BMJ. 2010;341:c6839.

Van Gorp T, Cadron I, Despierre E, Daemen A, Leunen K, Amant F, et al. HE4 and CA125 as a diagnostic test in ovarian cancer: prospective validation of the risk of ovarian malignancy algorithm. Br J Cancer. 2011;104(5):863-70.

Moore LE, Pfeiffer RM, Zhang Z, Lu KH, Fung ET, Bast RC Jr. Proteomic biomarkers in combination with CA 125 for detection of epithelial ovarian cancer using prediagnostic serum samples from the Prostate, Lung, Colorectal, and Ovarian (PLCO) cancer screening trial. Cancer. 2012;118:91-100.

Polterauer S, Grimm C, Seebacher V, Concin N, Marth C, Tomovski C, et al. Plasma fibrinogen levels and prognosis in patients with ovarian cancer: a multicenter study. The Oncologist. 2009a;14(10):979-85.

Polterauer S, Seebacher V, Hefler-Frischmuth K, Grimm C, Heinze G, Tempfer C, et al. Fibrinogen plasma levels are an independent prognostic parameter in patients with cervical cancer. Am J Obstet Gynecol. 2009;200(6):647.e1-7.

Seebacher V, Polterauer S, Grimm C, Husslein H, Leipold H, Hefler-Frischmuth K, et al. The prognostic value of plasma fibrinogen levels in patients with endometrial cancer: a multi-centre trial. Br J Cancer. 2010;102(6):952-6.

Qui J, Yu Y, Fu Y, Feng Y, Xie X, Lu W. Preoperative plasma fibrinogen, platelet count and prognosis in epithelial ovarian cancer. J Obstet Gynaecol Res. 2012;38(4):651-7.

Hefler-Frischmuth K, Lafleur J, Hefler L, Polterauer S, Seebacher V, Reinthaller A, et al. Plasma fibrinogen levels in patients with benign and malignant ovarian tumors. Gynecol Oncol. 2015;136(3):567-70.

Koh SC, Khalil R, Lim FK, Ilancheran A, Choolani M. The association between fibrinogen, von Willebrand Factor, antithrombin III, and D-dimer levels and survival outcome by 36 months from ovarian cancer. Clin Appl Thromb Hemost. 2006;12(1):3-8.

Feng Z, Wen H, Bi R, Duan Y, Yang W, Wu X. Thrombocytosis and hyperfibrinogenemia are predictive factors of clinical outcomes in high-grade serous ovarian cancer patients. BMC Cancer. 2016;16(1):43.

Ueland FR, DeSimone CP, Seamon LG, Miller RA, Goodrich S, Podzielinski I, et al. Effectiveness of a multivariate index assay in the preoperative assessment of ovarian tumors. Obstet Gynecol. 2011;117(6):1289-97.

Kaijser J, Sayasneh A, Van Hoorde K, Ghaem-Maghami S, Bourne T, Timmerman D, et al. Presurgical diagnosis of adnexal tumours using mathematical models and scoring systems: a systematic review and meta-analysis. Hum Reprod Update. 2014;20(3):449-62.

Seebacher V, Aust S, D’Andrea D, Grimm C, Reiser E, Tiringer D, et al. Development of a tool for prediction of ovarian cancer in patients with adnexal masses: Value of plasma fibrinogen. PLoS One. 2017;12(8):e0182383.

Nolen BM and Lokshin AE. Biomarker testing for ovarian cancer: clinical utility of multiplex assays. Mol Diagn Ther. 2013;17:139-46.

Moore RG, Miller MC, Disilvestro P, Landrum LM, Gajewski W, Ball JJ, et al. Evaluation of the diagnostic accuracy of the risk of ovarian malignancy algorithm in women with a pelvic mass. Obstet Gynecol. 2011;118(2 Pt 1):220-8.